



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/736,191	12/15/2003	Robert A. Rowland III	17090.002001	4366

7590 02/27/2006

Jonathan P. Osha  
ROSENTHAL & OSHA L.L.P.  
Suite 2800  
1221 McKinney  
Houston, TX 77010

EXAMINER

GIBSON, ROY DEAN

ART UNIT

PAPER NUMBER

3739

DATE MAILED: 02/27/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

CA

<b>Office Action Summary</b>	<b>Application No.</b> 10/736,191	<b>Applicant(s)</b> ROWLAND, ROBERT A.	
	<b>Examiner</b> Roy D. Gibson	<b>Art Unit</b> 3739	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 17 October 2005.
- 2a) ☐ This action is FINAL.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-24 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) 1-5, 7-19 and 21-24 is/are rejected.
- 7) ☐ Claim(s) 6 and 20 is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |   |   |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)  | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date <u>9/9/2005</u> | 6) <input type="checkbox"/> Other: _____  |

### **DETAILED ACTION**

This Office action addresses claims 18-24 which were overlooked in the last Office action, therefore, this action is non-final.

#### ***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-5, 7, 18-19 and 21-24 rejected under 35 U.S.C. 102(e) as being anticipated by Azar (US 2004/0167498).

As to claim 1, Azar discloses a method for treating acne (caused by an infection), therefore, inherently inhibiting an infection, comprising the steps:

(a) causing a rapid temperature change in a suspected area of infection by irradiating the skin with pulses of light (10-100 msec at a fluence of 10-100 Joules/sq. cm in order to reach a predetermined temperature);

(b) discontinuing the causing of the rapid temperature change; and

(c) assessing the suspected area for occurrence of infection (determine if the hair is removed, thus the acne related structures are at least partially destroyed and [0099-0109] , [0113-0117] and [0129]).

Art Unit: 3739

Further to claims 4-5, it would be inherent in the method to ask the patient if any discomfort is realized and the level of the discomfort.

Further to claim 7, it would be inherent in the method to repeat steps (a) –(c) if step (c) indicates that infection may still occur.

Claims 8-17 are rejected under 35 U.S.C. 102(b) as being anticipated by Macher et al. (6,066,164).

As to claims 8-9, Macher disclose a heating device comprising:

a heat transfer element (Figure 1, # 2) which can be positioned on the skin of a patient; and

a thermal energy source (heater #3) for altering a temperature of the surface of the heat transfer element until a predetermined temperature is reached and wherein the source forms an integral unit with the heat transfer element (col. 4, line 4-col. 7, line 31).

As to claims 10-12, Macher et al. further disclose the surface of the heat transfer element is configured to a shape of a target area; further comprising a temperature detector (sensor #36) which regulates activation of the thermal energy source.

As to claims 13, Macher et al. further disclose at least one input from the external power supply.

Art Unit: 3739

As to claims 14-17, Macher et al. further disclose and insulating element (21), a positioning element (Figure 3, # 4) for gripping the device, and wherein the thermal energy source is separately replaceable, and wherein the thermal energy source includes an input for renewal of at least one component of the thermal energy source (a means to replace the heater #3 and col. 4, line 4-col. 7, line 31).

Note that the phrase in the beginning of claim 8, i.e., an apparatus for inhibiting infection, is merely intended use and the device of Macher et al. is fully capable of meeting the claim limitations.

#### ***Allowable Subject Matter***

Claims 6 and 20 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Roy D. Gibson whose telephone number is 571-272-4767. The examiner can normally be reached on Tu-Th, 7:30 am-4:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Linda Dvorak can be reached on 571-272-4764. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3739

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

A handwritten signature in black ink, reading "Roy D. Gibson". The signature is written in a cursive, flowing style.

Roy D. Gibson  
Primary Examiner  
Art Unit 3739

February 21, 2006